National Institute for Health and Care Excellence

Draft for consultation

Depression in adults

[Supplement B3] Forest plots for first-line treatment of more severe depression

NICE guideline CG90 (update)

Evidence review supplement

November 2021

Draft for consultation

This evidence review supplement was developed by the National Guideline Alliance which is a part of the Royal College of Obstetricians and Gynaecologists

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive. All NICE guidance is subject to regular review and may be updated or withdrawn.

ISBN:

Contents

Forest plots for first-line treatment of more severe depression

Appendix E – Forest plots

More severe: Behavioural activation (BA) individual versus no treatment

Figure 1: Remission (ITT)



Figure 2: Discontinuation (any reason)



Figure 3: Depression symptomatology at 9-month follow-up



Figure 4: Remission at 9-month follow-up (ITT)



More severe: Behavioural therapies individual versus cognitive and cognitive behavioural therapies individual

Figure 5: Depression symptomatology endpoint



Figure 6: Depression symptomatology change score



Figure 7: Remission (ITT)



Figure 8: Discontinuation (any reason)



Test for subgroup differences: Not applicable

Figure 9: Depression symptomatology at 2-6 month follow-up



Figure 10: Interpersonal functioning endpoint



Test for subgroup differences: Not applicable

More severe: Behavioural activation (BA) individual versus any psychotherapy

Figure 11: Depression symptomatology endpoint



Figure 12: Depression symptomatology change score



Figure 13: Remission (ITT)



Figure 14: Response (ITT)



Figure 15: Discontinuation (any reason)



Figure 16: Quality of life endpoint



Figure 17: Quality of life physical health component endpoint



Figure 18: Quality of life mental health component endpoint



More severe: Behavioural activation (BA) individual versus sertraline

Figure 19: Remission (ITT)



Figure 20: Response (ITT)



Figure 21: Discontinuation (any)



Figure 22: Remission at 8-month follow-up (ITT)



Figure 23: Response at 8-month follow-up (ITT)



More severe: Behavioural activation (BA) individual + amitriptyline versus amitriptyline

Figure 24: Depression symptomatology endpoint



Figure 25: Depression symptomatology change score



Figure 26: Depression symptomatology at 6-month follow-up



More severe: Behavioural activation (BA) individual + any AD versus counselling + any AD

Figure 27: Depression symptomatology endpoint



Figure 28: Depression symptomatology change score



Figure 29: Discontinuation (any reason)



More severe: Behavioural activation (BA) individual + amitriptyline versus progressive muscle relaxation + amitriptyline

Figure 30: Depression symptomatology endpoint



Figure 31: Depression symptomatology change score



Figure 32: Depression symptomatology at 6-month follow-up



More severe: Coping with Depression course (group) versus waitlist

Figure 33: Discontinuation (any reason)

More severe: Cognitive and cognitive behavioural therapies individual versus no treatment

Figure 34: Depression symptomatology endpoint



Figure 35: Depression symptomatology change score



Figure 36: Remission (ITT)



Figure 37: Discontinuation (any reason)



Figure 38: Depression symptomatology at 3-6 month follow-up



Figure 39: Depression symptomatology at 9-month follow-up



Figure 40: Remission at 6-9 month follow-up (ITT)



Figure 41: Functional impairment endpoint



Figure 42: Functional impairment at 6-month follow-up



More severe: Cognitive and cognitive behavioural therapies individual versus waitlist

Figure 43: Depression symptomatology endpoint



Figure 44: Depression symptomatology change score



Figure 45: Discontinuation (any reason)



More severe: Cognitive and cognitive behavioural therapies individual versus TAU

Figure 46: Depression symptomatology endpoint



Figure 47: Depression symptomatology change score



Figure 48: Remission (ITT)



Figure 49: Discontinuation (any reason)



Figure 50: Depression symptomatology at 8-month follow-up



Figure 51: Interpersonal problems endpoint



Figure 52: Interpersonal problems at 8-month follow-up



Figure 53: Functional impairment endpoint



More severe: CBT individual (15 sessions or over) versus IPT

Figure 54: Depression symptomatology endpoint



Figure 55: Depression symptomatology change score



Figure 56: Remission (ITT)

Figure 57: Discontinuation (any reason)



Figure 58: Global functioning endpoint



Figure 59: Interpersonal problems endpoint



More severe: CBT individual (under 15 sessions) versus counselling

Figure 60: Depression symptomatology endpoint



Figure 61: Depression symptomatology change score



Figure 62: Discontinuation (any reason)



Figure 63: Depression symptomatology at 3-month follow-up



Figure 64: Depression symptomatology at 8-9 month follow-up



Figure 65: Interpersonal problems endpoint



Figure 66: Interpersonal problems at 8-month follow-up



More severe: CBT individual (under 15 sessions) versus computerised-CBT (CCBT)

Figure 67: Depression symptomatology endpoint



Figure 68: Depression symptomatology change score



Figure 69: Discontinuation (any reason)



Figure 70: Depression symptomatology at 3-month follow-up



Figure 71: Depression symptomatology at 9-month follow-up



Figure 72: Remission at 9-month follow-up (ITT)



More severe: Cognitive and cognitive behavioural therapies individual versus self-help with support

Figure 73: Depression symptomatology endpoint



Figure 74: Depression symptomatology change score



Figure 75: Remission (ITT)



Figure 76: Discontinuation (any reason)



Figure 77: Depression symptomatology at 3-month follow-up



Figure 78: Depression symptomatology at 6-month follow-up



Test for subgroup differences: Not applicable

Figure 79: Depression symptomatology change score at 3-month follow-up



Test for subgroup differences: Not applicable

Figure 80: Depression symptomatology change score at 6-month follow-up



Test for subgroup differences: Not applicable

Figure 81: Quality of life endpoint



Test for subgroup differences: Not applicable

Figure 82: Global functioning endpoint



Test for subgroup differences: Not applicable

Figure 83: Global functioning at 3-month follow-up



Test for subgroup differences: Not applicable

Figure 84: Global functioning at 6-month follow-up



Test for subgroup differences: Not applicable

Figure 85: Interpersonal problems endpoint



Test for subgroup differences: Chi² = 1.60, df = 1 (P = 0.21), I² = 37.3%

Figure 86: Interpersonal problems at 3-month follow-up



Test for subgroup differences: Not applicable

Figure 87: Interpersonal problems at 6-month follow-up



More severe: Dialectical behavioural therapy (DBT) individual versus CBT group (under 15 sessions)

Figure 88: Depression symptomatology endpoint



Figure 89: Depression symptomatology change score



More severe: Cognitive and cognitive behavioural therapies individual versus SSRI

Figure 90: Depression symptomatology endpoint



Figure 91: Depression symptomatology change score



Figure 92: Remission (ITT)



Test for subgroup differences: Not applicable

Figure 93: Discontinuation (any reason)



Test for subgroup differences: Not applicable

Figure 94: Quality of life endpoint



Test for subgroup differences: Not applicable

Figure 95: Functional impairment endpoint



Test for subgroup differences: Not applicable

More severe: Cognitive and cognitive behavioural therapies individual versus TCA

Figure 96: Depression symptomatology endpoint



Figure 97: Depression symptomatology change score



Figure 98: Remission (ITT)



Figure 99: Discontinuation (any reason)



Figure 100: Depression symptomatology at 1-month follow-up



Figure 101: Depression symptomatology at 12-month follow-up



Figure 102: Remission at 12-month follow-up (ITT)



Test for subgroup differences: Not applicable

Figure 103: Global functioning endpoint



Test for subgroup differences: Not applicable

Figure 104: Interpersonal problems endpoint



Test for subgroup differences: Not applicable

More severe: CBT individual (15 sessions or over) versus venlafaxine

Figure 105: Depression symptomatology endpoint



Figure 106: Depression symptomatology change score



Figure 107: Remission (ITT)



Figure 108: Response (ITT)



Figure 109: Discontinuation (any reason)



More severe: CBT individual (15 sessions or over) versus any AD

Figure 110: Depression symptomatology endpoint



Figure 111: Depression symptomatology change score



Figure 112: Remission (ITT)



Figure 113: Discontinuation (any reason)



More severe: CBT individual (15 sessions or over) versus pill placebo

Figure 114: Depression symptomatology endpoint



Figure 115: Depression symptomatology change score



Figure 116: Remission (ITT)



Figure 117: Discontinuation (any reason)



Figure 118: Global functioning endpoint



Figure 119: Interpersonal problems endpoint



More severe: Cognitive and cognitive behavioural therapies individual + AD versus AD

Figure 120: Depression symptomatology endpoint



Figure 121: Depression symptomatology change score



Figure 122: Remission (ITT)



Figure 123: Response (ITT)



Test for subgroup differences: Not applicable

Figure 124: Discontinuation due to SE



Test for subgroup differences: Chi² = 1.21, df = 1 (P = 0.27), I² = 17.7%

Figure 125: Discontinuation due to any reason (including SE)



Figure 126: Depression symptomatology at 3-month follow-up



Test for subgroup differences: Not applicable

Figure 127: Depression symptomatology at 6-12 month follow-up



Test for subgroup differences: Chi² = 0.00, df = 1 (P = 1.00), I² = 0%

Figure 128: Global functioning endpoint



Test for subgroup differences: Not applicable

Figure 129: Functional impairment endpoint



Test for subgroup differences: Not applicable

More severe: Cognitive and cognitive behavioural therapies individual + SSRI versus TAU

Figure 130: Depression symptomatology endpoint



Figure 131: Depression symptomatology change score



Figure 132: Remission (ITT)



Figure 133: Discontinuation due to any reason



Figure 134: Quality of life endpoint



Figure 135: Functional impairment endpoint



More severe: CBT group (under 15 sessions) versus no treatment

Figure 136: Depression symptomatology endpoint



Figure 137: Depression symptomatology change score



Figure 138: Depression symptomatology at 6-month follow-up



More severe: CBT group (under 15 sessions) versus waitlist

Figure 139: Depression symptomatology endpoint



Figure 140: Depression symptomatology change score



Figure 141: Discontinuation due to any reason



More severe: CBT group (under 15 sessions) versus TAU

Figure 142: Depression symptomatology endpoint



Figure 143: Depression symptomatology change score



Figure 144: Discontinuation due to any reason



Figure 145: Remission at 9-month follow-up (ITT)



More severe: CBT group (under 15 sessions) versus behavioural activation (BA) group

Figure 146: Depression symptomatology endpoint



Figure 147: Discontinuation du to any reason



Figure 148: Depression symptomatology at 1-month follow-up



More severe: CBT group (under 15 sessions) versus cognitive bibliotherapy

Figure 149: Depression symptomatology endpoint



Figure 150: Depression symptomatology change score



Figure 151: Discontinuation due to any reason



Figure 152: Depression symptomatology at 2-month follow-up



More severe: CBT group (under 15 sessions) versus cognitive bibliotherapy with support

Figure 153: Depression symptomatology endpoint



Figure 154: Depression symptomatology change score



Figure 155: Discontinuation due to any reason



Figure 156: Depression symptomatology at 2-month follow-up



More severe: CBT group (under 15 sessions) versus fluoxetine

Figure 157: Depression symptomatology endpoint



Figure 158: Remission (ITT)



Figure 159: Response (ITT)



Figure 160: Discontinuation due to any reason



Figure 161: Depression symptomatology at 3-month follow-up



Figure 162: Remission at 3-month follow-up (ITT)



Figure 163: Response at 3-month follow-up (ITT)



Figure 164: Quality of life endpoint



Figure 165: Quality of life at 3-month follow-up



More severe: CBT group (under 15 sessions) versus any AD

Figure 166: Depression symptomatology endpoint



Figure 167: Depression symptomatology change score



Figure 168: Discontinuation due to any reason



Figure 169: Remission at 9-month follow-up (ITT)

More severe: CBT group (under 15 sessions) + any AD versus any AD

Figure 170: Depression symptomatology endpoint



Figure 171: Depression symptomatology change score



Figure 172: Discontinuation due to SE



Figure 173: Discontinuation due to any reason including SE



Figure 174: Depression symptomatology at 6-month follow-up



More severe: Problem solving individual versus waitlist

Figure 175: Depression symptomatology endpoint



Figure 176: Depression symptomatology change score



Figure 177: Discontinuation due to any reason



Figure 178: Depression symptomatology at 2-month follow-up



More severe: Problem solving individual versus attention placebo

Figure 179: Depression symptomatology endpoint



Figure 180: Depression symptomatology change score



Figure 181: Discontinuation due to any reason



Figure 182: Depression symptomatology at 3-month follow-up



Figure 183: Depression symptomatology at 6-month follow-up



Figure 184: Functional impairment endpoint



Figure 185: Functional impairment at 3-month follow-up



Figure 186: Functional impairment at 6-month follow-up



More severe: Problem solving individual versus counselling

Figure 187: Depression symptomatology at endpoint



Figure 188: Depression symptomatology change score



Figure 189: Remission (ITT)



Figure 190: Response (ITT)



Figure 191: Discontinuation due to any reason



Figure 192: Functional impairment at endpoint



More severe: Problem solving individual versus any SSRI

Figure 193: Depression symptomatology endpoint



Figure 194: Remission (ITT)



Figure 195: Discontinuation due to any reason



Figure 196: Depression symptomatology at 9-month follow-up



Figure 197: Remission at 9-month follow-up (ITT)



More severe: Problem solving individual versus amitriptyline

Figure 198: Depression symptomatology endpoint



Figure 199: Depression symptomatology change score



Figure 200: Remission (ITT)



Figure 201: Discontinuation due to any reason



More severe: Problem solving individual versus pill placebo

Figure 202: Depression symptomatology endpoint



Figure 203: Depression symptomatology change score



Figure 204: Remission (ITT)



Figure 205: Discontinuation due to any reason



More severe: Problem solving individual + any SSRI versus any SSRI

Figure 206: Depression symptomatology endpoint



Figure 207: Remission (ITT)



Figure 208: Discontinuation due to SE



Figure 209: Discontinuation due any reason including SE



Figure 210: Depression symptomatology at 9-month follow-up



Figure 211: Remission at 9-month follow-up (ITT)



More severe: Problem solving group versus waitlist

Figure 212: Depression symptomatology endpoint



Figure 213: Depression symptomatology change score



Figure 214: Remission (ITT)



Figure 215: Discontinuation due to any reason



More severe: Counselling versus no treatment

Figure 216: Depression symptomatology endpoint



Figure 217: Depression symptomatology change score



Figure 218: Response (ITT)



Figure 219: Discontinuation due to any reason

Figure 220: Depression symptomatology at 5-month follow-up



Figure 221: Response at 5-month follow-up (ITT)



Figure 222: Functional impairment endpoint



Figure 223: Functional impairment at 5-month follow-up



More severe: Counselling versus TAU

Figure 224: Depression symptomatology endpoint



Figure 225: Depression symptomatology change score



Figure 226: Discontinuation due to any reason



Figure 227: Depression symptomatology at 8-month follow-up



Figure 228: Interpersonal problems endpoint



Figure 229: Interpersonal problems at 8-month follow-up



More severe: Counselling versus computerised-CBT (CCBT)

Figure 230: Depression symptomatology endpoint



Figure 231: Depression symptomatology change score



Figure 232: Depression symptomatology at 3-month follow-up



Figure 233: Depression symptomatology at 9-month follow-up



More severe: Counselling versus any AD

Figure 234: Depression symptomatology endpoint



Figure 235: Remission (ITT)



Figure 236: Discontinuation due to any reason



Figure 237: Depression symptomatology at 10-month follow-up



Figure 238: Remission at 10 months follow-up (ITT)



More severe: IPT versus any AD

Figure 239: Depression symptomatology endpoint



Figure 240: Depression symptomatology change score



More severe: Interpersonal counselling individual versus any SSRI

Figure 241: Remission (ITT)



Figure 242: Discontinuation due to any reason



More severe: IPT versus imipramine

Figure 243: Depression symptomatology endpoint



Figure 244: Depression symptomatology change score



Figure 245: Remission (ITT)



Figure 246: Discontinuation due to any reason



Figure 247: Global functioning endpoint



Figure 248: Interpersonal problems endpoint



More severe: IPT versus pill placebo

Figure 249: Depression symptomatology endpoint



Figure 250: Depression symptomatology change score



Figure 251: Remission (ITT)



Figure 252: Discontinuation due to any reason



Figure 253: Global functioning endpoint



Figure 254: Interpersonal problems endpoint



1 More severe: IPT + AD versus AD

2 Figure 255: Depression symptomatology endpoint



3

4 Figure 256: Depression symptomatology change score



5

Figure 257: Remission (ITT)



Figure 258: Discontinuation due to SE



Figure 259: Discontinuation due to any reason including SE



Figure 260: Remission at 3-month follow-up (ITT)



Figure 261: Remission at 9-month follow-up (ITT)<Insert graphic title here>



Figure 262: Global functioning endpoint



More severe: IPT + any AD versus psychoeducation group + any AD

Figure 263: Depression symptomatology change score



Figure 264: Remission (ITT)



Figure 265: Discontinuation due to any reason



Figure 266: Remission at 3-month follow-up (ITT)



Figure 267: Remission at 9-month follow-up (ITT)



More severe: Computerised-CBT (CCBT) versus no treatment

Figure 268: Depression symptomatology endpoint



Figure 269: Depression symptomatology change score



Figure 270: Discontinuation due to any reason



Figure 271: Depression symptomatology at 3-month follow-up



Figure 272: Depression symptomatology at 9-month follow-up



Figure 273: Remission at 9-month follow-up (ITT)



Figure 274: Quality of life endpoint



More severe: Self-help versus waitlist

Figure 275: Depression symptomatology endpoint



Figure 276: Depression symptomatology change score



Figure 277: Remission (ITT)



Figure 278: Response (ITT)



Figure 279: Discontinuation due to any reason



Figure 280: Functional impairment endpoint



More severe: Computerised-CBT (CCBT) versus enhanced TAU

Figure 281: Depression symptomatology endpoint



Figure 282: Discontinuation due to any reason



Figure 283: Depression symptomatology at 6-month follow-up



Figure 284: Quality of life endpoint



Figure 285: Quality of life at 6-month follow-up



Figure 286: Quality of life at 12-month follow-up



More severe: Computerised attentional bias modification versus attention placebo

Figure 287: Depression symptomatology endpoint



Figure 288: Depression symptomatology change score



1 More severe: Self-help + AD versus AD

2 Figure 289: Depression symptomatology endpoint



3 Test for subgroup differences: Not applicable

4 Figure 290: Remission (ITT)



5 Test for subgroup differences: Not applicable

6 Figure 291: Response (ITT)



7 Test for subgroup differences: Not applicable

8 Figure 292: Discontinuation due to any reason



9 Test for subgroup differences: Not applicable

Figure 293: Quality of life physical health component endpoint



Test for subgroup differences: Not applicable

Figure 294: Quality of life mental health component endpoint



Test for subgroup differences: Not applicable

Figure 295: Depression symptomatology at 8-month follow-up



Test for subgroup differences: Not applicable

Figure 296: Depression symptomatology at 20-month follow-up



Test for subgroup differences: Not applicable

Figure 297: Remission at 8-month follow-up (ITT)



Test for subgroup differences: Not applicable

Figure 298: Remission at 20-month follow-up (ITT)



Test for subgroup differences: Not applicable

Figure 299: Quality of life physical health component at 8-month follow-up



Test for subgroup differences: Not applicable

Figure 300: Quality of life mental health component at 8-month follow-up



Test for subgroup differences: Not applicable

Figure 301: Quality of life physical health component at 20-month follow-up



Test for subgroup differences: Not applicable

Figure 302: Quality of life mental health component at 20-month follow-up



Test for subgroup differences: Not applicable

More severe: Computerised-CBT (CCBT) with support versus no treatment

Figure 303: Depression symptomatology endpoint



Figure 304: Depression symptomatology change score



Figure 305: Remission (ITT)



Figure 306: Discontinuation due to any reason



Figure 307: Quality of life endpoint



More severe: Self-help with support versus waitlist

Figure 308: Depression symptomatology endpoint



Figure 309: Depression symptomatology change score



Figure 310: Remission (ITT)



Figure 311: Response (ITT)



Test for subgroup differences: Not applicable

Figure 312: Discontinuation due to any reason



Test for subgroup differences: Chi² = 0.12, df = 1 (P = 0.73), I² = 0%

Figure 313: Quality of life endpoint



Test for subgroup differences: Not applicable

Figure 314: Functional impairment endpoint



Test for subgroup differences: Not applicable

Figure 315: Sleeping difficulties endpoint



More severe: Self-help with support versus self-help (without support)

Figure 316: Depression symptomatology endpoint



Figure 317: Depression symptomatology change score



Figure 318: Remission (ITT)



Figure 319: Discontinuation due to any reason



Figure 320: Depression symptomatology at 2-3 month follow-up



Figure 321: Depression symptomatology at 6-month follow-up



Figure 322: Quality of life endpoint



Figure 323: Quality of life at 3-month follow-up



Figure 324: Quality of life at 6-month follow-up



More severe: Short-term psychodynamic psychotherapies individual versus any psychotherapy

Figure 325: Depression symptomatology endpoint



Figure 326: Depression symptomatology change score



Figure 327: Discontinuation due to any reason



More severe: Short-term psychodynamic psychotherapy individual versus cognitive and cognitive behavioural therapies individual

Figure 328: Depression symptomatology endpoint



Figure 329: Depression symptomatology change score



Figure 330: Remission (ITT)



Figure 331: Discontinuation due to any reason



Figure 332: Quality of life endpoint



Figure 333: Quality of life physical health component endpoint



Figure 334: Quality of life mental health component endpoint



Figure 335: Interpersonal problems endpoint



Figure 336: Remission at 3-month follow-up (ITT)



More severe: Dynamic interpersonal therapy (DIT) individual versus cognitive bibliotherapy with support

Figure 337: Depression symptomatology endpoint



Figure 338: Depression symptomatology change score



Figure 339: Remission (ITT)



Figure 340: Discontinuation due to any reason



Figure 341: Quality of life endpoint



Figure 342: Interpersonal problems endpoint



More severe: Short-term psychodynamic psychotherapies individual versus fluoxetine

Figure 343: Depression symptomatology change score



Figure 344: Remission (ITT)



Figure 345: Discontinuation due to any reason



Figure 346: Global functioning change score



More severe: Short-term psychodynamic psychotherapy individual + any AD versus any AD

Figure 347: Depression symptomatology endpoint



Figure 348: Depression symptomatology change score



Figure 349: Quality of life endpoint



More severe: Short-term psychodynamic psychotherapy individual + AD versus counselling + AD

Figure 350: Depression symptomatology endpoint



Figure 351: Depression symptomatology change score



Figure 352: Remission (ITT)



Figure 353: Response (ITT)



Figure 354: Discontinuation due to any reason



Figure 355: Depression symptomatology at 3-6 month follow-up



Figure 356: Remission at 3-6 month follow-up (ITT)



Figure 357: Response at 3-6 month follow-up (ITT)



Figure 358: Functional impairment endpoint



Figure 359: Functional impairment at 3-month follow-up



More severe: Short-term psychodynamic psychotherapy group versus cognitive and cognitive behavioural therapies group

Figure 360: Remission (ITT)



More severe: Long-term psychodynamic psychotherapy individual versus fluoxetine

Figure 361: Depression symptomatology endpoint



Figure 362: Remission (ITT)



Figure 363: Discontinuation due to any reason



More severe: Long-term psychodynamic psychotherapy individual + fluoxetine versus fluoxetine

Figure 364: Depression symptomatology endpoint



Figure 365: Remission (ITT)



Figure 366: Discontinuation due to any reason



More severe: Music therapy group versus no treatment

Figure 367: Depression symptomatology at endpoint



Figure 368: Depression symptomatology change score



Figure 369: Discontinuation due to any reason



More severe: Peer support group versus any AD

Figure 370: Depression symptomatology endpoint



Figure 371: Depression symptomatology change score



Figure 372: Remission (ITT)



Figure 373: Discontinuation due to any reason



Figure 374: Depression symptomatology at 6-month follow-up



Figure 375: Remission at 6-month follow-up (ITT)

More severe: Peer support group + any AD versus any AD

Figure 376: Depression symptomatology endpoint



Figure 377: Depression symptomatology change score



Figure 378: Remission (ITT)



Figure 379: Discontinuation due to any reason



Figure 380: Depression symptomatology at 6-month follow-up



Figure 381: Remission at 6-month follow-up (ITT)



More severe: Psychoeducation group versus no treatment

Figure 382: Depression symptomatology endpoint



Figure 383: Depression symptomatology change score



Figure 384: Discontinuation due to any reason

More severe: Psychoeducation group + any AD versus any AD

Figure 385: Depression symptomatology change score



Figure 386: Remission (ITT)



Figure 387: Discontinuation due to any reason



Figure 388: Remission at 3-month follow-up (ITT)



Figure 389: Remission at 9-month follow-up (ITT)



More severe: Mindfulness-based cognitive therapy (MBCT) group versus no treatment

Figure 390: Depression symptomatology endpoint



Figure 391: Depression symptomatology change score



More severe: Progressive muscle relaxation + amitriptyline versus amitriptyline

Figure 392: Depression symptomatology endpoint



Figure 393: Depression symptomatology change score



Figure 394: Depression symptomatology at 6-month follow-up



1 More severe: SSRIs versus no treatment

2 Figure 395: Depression symptomatology endpoint



3 Test for subgroup differences: Not applicable

4 Figure 396: Depression symptomatology change score



5 Test for subgroup differences: Not applicable

6 Figure 397: Discontinuation due to any reason



7 Test for subgroup differences: Not applicable

8 Figure 398: Quality of life physical health component endpoint



9 Test for subgroup differences: Not applicable

1 **Figure 399: Quality of life mental health component endpoint**



2 Test for subgroup differences: Not applicable

3

1 More severe: SSRIs versus placebo

2 Figure 400: Depression symptomatology endpoint



3

4

5

6

7

Figure 401: Depression symptomatology change score



Figure 402: Remission (ITT)



Figure 403: Response (ITT)



Figure 404: Discontinuation due to SE



Figure 405: Discontinuation due to any reason including SE



Figure 406: Remission at 12-month follow-up (ITT)



Test for subgroup differences: Not applicable

Figure 407: Quality of life change score



Test for subgroup differences: Not applicable

Figure 408: Global functioning endpoint



Test for subgroup differences: Not applicable

Figure 409: Functional impairment change score



Test for subgroup differences: Not applicable

Figure 410: Sleeping difficulties change score endpoint



Test for subgroup differences: Not applicable

1 More severe: SSRIs versus TCAs

2 Figure 411: Depression symptomatology endpoint


Experimental
Control
Std. Mean Difference
Std. Mean Difference
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI
IV, Random, 95% CI
77.1.1 Fluoxetine versus amitriptyline
Demyttenaere 1998 9.9 6.3 35 7.2 4.5 31 2.7% 0.48 [-0.01, 0.97]
De Ronchi 1998 14.22 8.31 32 13.94 9.4 33 2.7% 0.03 [-0.46, 0.52]
Fawcett 1989 12.8 6.5 19 14.6 7.9 19 1.9% -0.24 [-0.88, 0.39]
Judd 1993 9.6 6.2 23 11.6 6 23 2.1% -0.32 [-0.90, 0.26]
Laakmann 1988 8.96 7.52 36 6.59 7.52 43 3.0% 0.31 [-0.13, 0.76]
Laakmann 1991 9.47 7.56 62 9.65 7.86 62 3.8% -0.02 [-0.38, 0.33]
Marchesi 1998 8.9 6.6 67 8.1 6.9 75 4.1% 0.12 [-0.21, 0.45]
Ontiveros Sanchez 1998 7.8 6.21 21 5.8 5.45 21 2.0% 0.34 [-0.27, 0.95]
Peters 1990 10 6 41 11 9 40 3.1% -0.13 [-0.57, 0.31]
Suleman 1997 7.2 2.5 15 7 2.6 15 1.6% 0.08 [-0.64, 0.79]
Versiani 1999 9.9 8.4 77 8.1 7 79 4.2% 0.23 [-0.08, 0.55]
Subtotal (95% CI) 428 441 31.2% 0.10 [-0.03, 0.24]
Heterogeneity: Tau² = 0.00; Chi² = 9.22, df = 10 (P = 0.51); I² = 0%
Test for overall effect: Z = 1.51 (P = 0.13)
77.1.2 Fluoxetine versus clomipramine
Noguera 1991 6.21 4.57 60 6.66 4.93 60 3.8% -0.09 [-0.45, 0.26]
Ropert 1989 9.4 7 54 11.8 8 46 3.4% -0.32 [-0.71, 0.08]
Subtotal (95% CI) 114 106 7.2% -0.20 [-0.46, 0.07]
Heterogeneity: Tau² = 0.00; Chi² = 0.68, df = 1 (P = 0.41); I² = 0%
Test for overall effect: Z = 1.44 (P = 0.15)
77.1.3 Fluoxetine versus imipramine
Byerley 1988 12.8 7.7 20 13.7 8.5 24 2.1% -0.11 [-0.70, 0.49]
Cohn 1984b 14.72 8.81 35 14.54 8.85 31 2.7% 0.02 [-0.46, 0.50]
Serrano-Blanco 2006 9.5 8.2 49 8.8 8.2 45 3.3% 0.08 [-0.32, 0.49]
Tollefson 1994 11.6 7.6 62 12.2 7.9 60 3.8% -0.08 [-0.43, 0.28]
Subtotal (95% CI) 166 160 12.0% -0.01 [-0.23, 0.20]
Heterogeneity: Tau² = 0.00; Chi² = 0.47, df = 3 (P = 0.93); I² = 0%
Test for overall effect: Z = 0.13 (P = 0.89)
77.1.4 Fluoxetine versus nortriptyline
Hashemi 2012 16.16 4.02 48 19.71 4.21 49 3.2% -0.86 [-1.27, -0.44]
Subtotal (95% CI) 48 49 3.2% -0.86 [-1.27, -0.44]
Heterogeneity: Not applicable
Test for overall effect: Z = 4.02 (P < 0.0001)
77.1.5 Paroxetine versus amitriptyline
Christiansen 1996 8.1 5.9 56 6.9 6.2 57 3.7% 0.20 [-0.17, 0.57]
Deushle 2003 12.7 8.2 40 10.5 7.1 40 3.0% 0.28 [-0.16, 0.72]
Freed 1999 13.7 10.24 149 16.58 10.89 157 5.3% -0.27 [-0.50, -0.05]
Moller 1993 11.5 8.3 72 9.3 6.3 68 4.0% 0.30 [-0.04, 0.63]
PAR 29060/281 16.1 8.59 76 12.4 8.59 79 4.2% 0.43 [0.11, 0.75]
PAR MDUK 032 12 8.07 29 12.2 8.07 30 2.5% -0.02 [-0.53, 0.49]
SER-CHN-1 5.53 6.94 113 6.47 7.24 118 4.9% -0.13 [-0.39, 0.13]
Staner 1995 17.8 11.3 21 10.7 7.9 19 1.8% 0.71 [0.07, 1.35]
Subtotal (95% CI) 556 568 29.6% 0.14 [-0.08, 0.37]
Heterogeneity: Tau² = 0.07; Chi² = 23.05, df = 7 (P = 0.002); I² = 70%
Test for overall effect: Z = 1.24 (P = 0.22)
77.1.6 Paroxetine versus imipramine
Arminen 1992 8.76 5.63 21 11.21 9.45 29 2.2% -0.30 [-0.86, 0.27]
Chiu 1996 7.4 9.6 15 11.7 8.1 15 1.5% -0.47 [-1.20, 0.26]
Subtotal (95% CI) 36 44 3.7% -0.36 [-0.81, 0.08]
Heterogeneity: Tau² = 0.00; Chi² = 0.14, df = 1 (P = 0.71); I² = 0%
Test for overall effect: Z = 1.60 (P = 0.11)
77.1.7 Paroxetine versus lofepramine
GSK_29060/103 13.5 11.4 45 13.8 8.4 36 3.1% -0.03 [-0.47, 0.41]
Subtotal (95% CI) 45 36 3.1% -0.03 [-0.47, 0.41]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
77.1.8 Paroxetine versus nortriptyline
Mulsant 1999 9.6 4.6 29 8.8 3 27 2.4% 0.20 [-0.32, 0.73]
Subtotal (95% CI) 29 27 2.4% 0.20 [-0.32, 0.73]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
77.1.9 Sertraline versus amitriptyline
Bersani 1994 16 6.5 31 16 6.1 30 2.6% 0.00 [-0.50, 0.50]
Subtotal (95% CI) 31 30 2.6% 0.00 [-0.50, 0.50]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
77.1.10 Sertraline versus imipramine
Bhargava 2012 14.23 3.51 30 13.67 4.74 30 2.6% 0.13 [-0.37, 0.64]
Forlenza 2001 14.44 12.35 27 12.71 11.8 28 2.4% 0.14 [-0.39, 0.67]
Subtotal (95% CI) 57 58 5.0% 0.14 [-0.23, 0.50]
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.98); I² = 0%
Test for overall effect: Z = 0.73 (P = 0.46)
Total (95% CI) 1510 1519 100.0% 0.02 [-0.08, 0.12]
Heterogeneity: Tau² = 0.04; Chi² = 58.61, df = 32 (P = 0.003); I² = 45%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Chi² = 25.77, df = 9 (P = 0.002), I² = 65.1%
-10 -5 0 5 10
Favours SSRI Favours TCA

1

Figure 412: Depression symptomatology change score



Figure 413: Remission (ITT)



Figure 414: Response (ITT)



Figure 415: Discontinuation due to SE



2

Figure 416: Discontinuation due to any reason including SE



Figure 417: Sleep endpoint



Test for subgroup differences: Not applicable

Figure 418: Functional impairment endpoint



Test for subgroup differences: Not applicable

More severe: Fluoxetine + long-term psychodynamic psychotherapy individual versus long-term psychodynamic psychotherapy individual

Figure 419: Depression symptomatology endpoint



Figure 420: Remission (ITT)



Figure 421: Discontinuation due to any reason



More severe: SSRI + psych intervention versus placebo + psych intervention

Figure 422: Depression symptomatology endpoint



Test for subgroup differences: Not applicable

Figure 423: Depression symptomatology change score



Figure 424: Remission (ITT)



Test for subgroup differences: Not applicable

Figure 425: Discontinuation due to SE



Figure 426: Discontinuation due to any reason including SE



More severe: Sertraline + supervised high intensity exercise individual versus supervised high intensity exercise individual

Figure 427: Depression symptomatology endpoint



Figure 428: Depression symptomatology change score



More severe: Fluoxetine + bright light therapy versus bright light therapy

Figure 429: Depression symptomatology change score



Figure 430: Remission (ITT)



Figure 431: Response (ITT)



Figure 432: Discontinuation due to SE



Figure 433: Discontinuation due to any reason including SE



1 More severe: TCAs versus placebo

2 Figure 434: Depression symptomatology endpoint



3

Figure 435: Depression symptomatology change score



Figure 436: Remission (ITT)



Figure 437: Response (ITT)



Figure 438: Discontinuation due to SE


Experimental
Control
Risk Ratio
Risk Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI
M-H, Random, 95% CI
82.5.1 Amitriptyline
29060 07 001 2 13 2 12 1.6% 0.92 [0.15, 5.56]
Amsterdam 1986 11 55 3 54 2.9% 3.60 [1.06, 12.20]
Bakish 1992b 10 59 5 56 3.7% 1.90 [0.69, 5.21]
Blashki 1971 7 35 4 23 3.2% 1.15 [0.38, 3.49]
Bremner 1995 5 50 2 50 1.9% 2.50 [0.51, 12.29]
Feighner 1979 12 93 3 50 2.9% 2.15 [0.64, 7.27]
Gelenberg 1990a 8 19 6 22 4.4% 1.54 [0.65, 3.66]
Goldberg 1980 2 60 2 62 1.4% 1.03 [0.15, 7.10]
Hicks 1988 0 16 0 15 Not estimable
McCallum 1975 1 12 2 12 1.1% 0.50 [0.05, 4.81]
MIR 003-020 (FDA) 10 43 8 43 4.6% 1.25 [0.55, 2.86]
MIR 003-021 (FDA) 9 50 9 50 4.5% 1.00 [0.43, 2.31]
Mynors-Wallis 1995 3 31 2 30 1.7% 1.45 [0.26, 8.09]
Reimherr 1990 28 149 3 150 3.0% 9.40 [2.92, 30.24]
SER 315 (FDA) 6 77 6 80 3.3% 1.04 [0.35, 3.08]
Smith 1990 10 50 0 50 0.7% 21.00 [1.26, 348.93]
Thomson 1982 7 31 0 28 0.7% 13.59 [0.81, 227.66]
Subtotal (95% CI) 843 787 41.6% 1.79 [1.21, 2.66]
Total events 131 57
Heterogeneity: Tau² = 0.20; Chi² = 22.51, df = 15 (P = 0.10); I² = 33%
Test for overall effect: Z = 2.90 (P = 0.004)
82.5.2 Imipramine
Byerley 1988 4 34 4 29 2.6% 0.85 [0.23, 3.11]
Cassano 1986 17 165 5 149 3.8% 3.07 [1.16, 8.12]
Cohn 1984a 3 21 1 21 1.1% 3.00 [0.34, 26.56]
Escobar 1980 0 15 0 12 Not estimable
Feiger 1996 12 41 0 40 0.7% 24.40 [1.49, 398.83]
Feighner 1989b 5 15 0 15 0.7% 11.00 [0.66, 182.87]
Feighner 1993 85 241 21 244 7.3% 4.10 [2.63, 6.38]
Fontaine 1994 6 45 1 45 1.2% 6.00 [0.75, 47.85]
Kleber 1983 0 23 0 23 Not estimable
Lecrubier 1997 10 75 4 76 3.2% 2.53 [0.83, 7.72]
March 1990 0 18 2 18 0.6% 0.20 [0.01, 3.89]
Norton 1984 0 30 0 25 Not estimable
Peselow 1989b 3 40 1 42 1.1% 3.15 [0.34, 29.04]
Philipp 1999 1 110 0 47 0.6% 1.30 [0.05, 31.28]
Rickels 1982e 7 51 3 46 2.6% 2.10 [0.58, 7.66]
Rickels 1991 13 64 5 67 3.8% 2.72 [1.03, 7.20]
Rickels 1994 20 92 8 95 4.9% 2.58 [1.20, 5.57]
Schweizer 1994 18 73 3 78 3.0% 6.41 [1.97, 20.86]
Schweizer 1998 2 60 3 60 1.6% 0.67 [0.12, 3.85]
Silverstone 1994 10 83 6 83 3.9% 1.67 [0.63, 4.38]
Stark 1985 52 186 8 169 5.3% 5.91 [2.89, 12.07]
Versiani 1989 7 164 1 162 1.2% 6.91 [0.86, 55.57]
Versiani 1990a 1 25 0 25 0.6% 3.00 [0.13, 70.30]
Subtotal (95% CI) 1671 1571 50.0% 3.07 [2.27, 4.15]
Total events 276 76
Heterogeneity: Tau² = 0.07; Chi² = 22.76, df = 19 (P = 0.25); I² = 17%
Test for overall effect: Z = 7.32 (P < 0.00001)
82.5.3 Nortriptyline
Georgotas 1986 2 28 0 30 0.6% 5.34 [0.27, 106.70]
Katz 1990 6 18 1 12 1.3% 4.00 [0.55, 29.17]
Nair 1995 10 38 1 35 1.3% 9.21 [1.24, 68.31]
Reynolds 1999a 2 25 1 22 1.0% 1.76 [0.17, 18.11]
Subtotal (95% CI) 109 99 4.3% 4.47 [1.46, 13.70]
Total events 20 3
Heterogeneity: Tau² = 0.00; Chi² = 1.17, df = 3 (P = 0.76); I² = 0%
Test for overall effect: Z = 2.62 (P = 0.009)
82.5.4 Lofepramine/imipramine
Rickels 1982b 22 106 5 52 4.1% 2.16 [0.87, 5.38]
Subtotal (95% CI) 106 52 4.1% 2.16 [0.87, 5.38]
Total events 22 5
Heterogeneity: Not applicable
Test for overall effect: Z = 1.65 (P = 0.10)
Total (95% CI) 2729 2509 100.0% 2.42 [1.89, 3.10]
Total events 449 141
Heterogeneity: Tau² = 0.17; Chi² = 57.57, df = 40 (P = 0.04); I² = 31%
Test for overall effect: Z = 7.02 (P < 0.00001)
Test for subgroup differences: Chi² = 5.60, df = 3 (P = 0.13), I² = 46.5%
0.01 0.1 1 10 100
Favours TCA Favours placebo

1

Figure 439: Discontinuation due to any reason including SE



Figure 440: Depression symptomatology at 6-month follow-up



Test for subgroup differences: Not applicable

Figure 441: Global functioning endpoint



Test for subgroup differences: Not applicable

Figure 442: Quality of life change score



Test for subgroup differences: Not applicable

Figure 443: Quality of life physical health component endpoint



Test for subgroup differences: Not applicable

Figure 444: Quality of life mental health component endpoint



Test for subgroup differences: Not applicable

1 **Figure 445: Interpersonal problems endpoint**



2

3

4 More severe: TCA + psych intervention versus psych 5 intervention

6 **Figure 446: Depression symptomatology endpoint**



7

8 **Figure 447: Depression symptomatology change score**



9

Figure 448: Remission (ITT)



Figure 449: Discontinuation due to any reason



Figure 450: Depression symptomatology at 1-month follow-up



Test for subgroup differences: Not applicable

Figure 451: Depression symptomatology at 12-month follow-up



Test for subgroup differences: Not applicable

Figure 452: Global functioning endpoint



Test for subgroup differences: Not applicable

More severe: TCA + psych intervention versus placebo + psych intervention

Figure 453: Depression symptomatology endpoint



Figure 454: Depression symptomatology change score



Figure 455: Remission (ITT)



Test for subgroup differences: Not applicable

Figure 456: Response (ITT)



Test for subgroup differences: Not applicable

Figure 457: Discontinuation due to SE



Test for subgroup differences: Not applicable

Figure 458: Discontinuation due to any reason including SE



Figure 459: Depression symptomatology at 1-month follow-up



Figure 460: Depression symptomatology at 6-month follow-up



More severe: SNRIs versus placebo

Figure 461: Depression symptomatology endpoint



Figure 462: Depression symptomatology change score



Figure 463: Remission (ITT)



Figure 464: Response (ITT)



Figure 465: Discontinuation due to SE



Figure 466: Discontinuation due to any reason including SE



Figure 467: Functional impairment change score



More severe: SNRIs versus TCAs

Figure 468: Depression symptomatology endpoint



Figure 469: Depression symptomatology change score



Figure 470: Remission (ITT)



Figure 471: Response (ITT)



Figure 472: Discontinuation due to SE



Figure 473: Discontinuation due to any reason including SE



More severe: SNRIs versus SSRIs

Figure 474: Depression symptomatology endpoint



Figure 475: Depression symptomatology change score



1 **Figure 476: Remission (ITT)**


Experimental
Control
Risk Ratio
Risk Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI
M-H, Random, 95% CI
87.3.1 Duloxetine versus escitalopram
Khan 2007 46 138 54 140 3.2% 0.86 [0.63, 1.18]
Nierenberg 2007 75 273 69 274 3.9% 1.09 [0.82, 1.44]
Wade 2007 102 151 103 144 12.2% 0.94 [0.81, 1.10]
Subtotal (95% CI) 562 558 19.3% 0.96 [0.85, 1.08]
Total events 223 226
Heterogeneity: Tau² = 0.00; Chi² = 1.31, df = 2 (P = 0.52); I² = 0%
Test for overall effect: Z = 0.69 (P = 0.49)
87.3.2 Duloxetine versus fluoxetine
Goldstein 2002 37 70 10 33 1.0% 1.74 [0.99, 3.06]
Study F1J-MC-HMAQ - Study Group B 32 82 11 37 1.0% 1.31 [0.75, 2.31]
Subtotal (95% CI) 152 70 2.0% 1.51 [1.02, 2.25]
Total events 69 21
Heterogeneity: Tau² = 0.00; Chi² = 0.49, df = 1 (P = 0.48); I² = 0%
Test for overall effect: Z = 2.04 (P = 0.04)
87.3.3 Duloxetine versus paroxetine
Detke 2004 92 188 38 86 4.0% 1.11 [0.84, 1.46]
Eli Lilly HMAT-A 23 84 31 89 1.6% 0.79 [0.50, 1.23]
Goldstein 2004 43 91 31 87 2.5% 1.33 [0.93, 1.89]
Hao 2014 51 140 42 141 2.8% 1.22 [0.87, 1.71]
Higuchi 2009 26 75 49 148 2.1% 1.05 [0.71, 1.54]
Lee 2007 117 238 121 240 9.0% 0.98 [0.81, 1.17]
Perahia 2006 82 196 42 97 3.9% 0.97 [0.73, 1.28]
Subtotal (95% CI) 1012 888 26.0% 1.04 [0.93, 1.16]
Total events 434 354
Heterogeneity: Tau² = 0.00; Chi² = 5.13, df = 6 (P = 0.53); I² = 0%
Test for overall effect: Z = 0.69 (P = 0.49)
87.3.4 Venlafaxine versus citalopram
Allard 2004 11 76 14 75 0.6% 0.78 [0.38, 1.60]
Subtotal (95% CI) 76 75 0.6% 0.78 [0.38, 1.60]
Total events 11 14
Heterogeneity: Not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
87.3.5 Venlafaxine versus escitalopram
Bielski 2004 36 101 40 101 2.5% 0.90 [0.63, 1.28]
Montgomery 2004 99 145 102 148 11.7% 0.99 [0.85, 1.16]
Subtotal (95% CI) 246 249 14.2% 0.98 [0.85, 1.12]
Total events 135 142
Heterogeneity: Tau² = 0.00; Chi² = 0.26, df = 1 (P = 0.61); I² = 0%
Test for overall effect: Z = 0.34 (P = 0.73)
87.3.6 Venlafaxine versus fluoxetine
Alves 1999 15 40 16 47 1.0% 1.10 [0.63, 1.94]
Costa 1998 118 196 112 186 10.7% 1.00 [0.85, 1.18]
DeNayer 2002 38 73 27 73 2.3% 1.41 [0.97, 2.04]
Kornaat 2000 26 79 19 77 1.3% 1.33 [0.81, 2.20]
Nemeroff 2007 31 102 28 104 1.7% 1.13 [0.73, 1.74]
Rickels 2000 9 27 10 24 0.6% 0.80 [0.39, 1.63]
Rudolph 1999 35 100 23 103 1.6% 1.57 [1.00, 2.45]
Schatzberg 2000 25 104 20 100 1.2% 1.20 [0.71, 2.02]
Sheehan 2009b 21 95 15 99 0.9% 1.46 [0.80, 2.66]
Tsai 2000 12 33 12 33 0.8% 1.00 [0.53, 1.89]
Tylee 1997 52 171 53 170 3.1% 0.98 [0.71, 1.34]
Tzanakaki 2000 18 55 15 54 1.0% 1.18 [0.66, 2.09]
Subtotal (95% CI) 1075 1070 26.2% 1.10 [0.99, 1.23]
Total events 400 350
Heterogeneity: Tau² = 0.00; Chi² = 8.60, df = 11 (P = 0.66); I² = 0%
Test for overall effect: Z = 1.76 (P = 0.08)
87.3.7 Venlafaxine versus paroxetine
Casabona 2004 18 58 20 56 1.2% 0.87 [0.52, 1.46]
Owens 2008 26 44 18 42 1.8% 1.38 [0.90, 2.11]
Subtotal (95% CI) 102 98 2.9% 1.12 [0.71, 1.77]
Total events 44 38
Heterogeneity: Tau² = 0.05; Chi² = 1.84, df = 1 (P = 0.18); I² = 46%
Test for overall effect: Z = 0.50 (P = 0.62)
87.3.8 Venlafaxine versus sertraline
Mehtonen 2000 40 75 27 72 2.4% 1.42 [0.99, 2.05]
Shelton 2006 37 78 29 82 2.3% 1.34 [0.92, 1.95]
Sir 2005 43 84 47 79 4.1% 0.86 [0.65, 1.14]
Subtotal (95% CI) 237 233 8.7% 1.16 [0.82, 1.63]
Total events 120 103
Heterogeneity: Tau² = 0.06; Chi² = 6.09, df = 2 (P = 0.05); I² = 67%
Test for overall effect: Z = 0.84 (P = 0.40)
Total (95% CI) 3462 3241 100.0% 1.05 [0.99, 1.11]
Total events 1436 1248
Heterogeneity: Tau² = 0.00; Chi² = 32.18, df = 31 (P = 0.41); I² = 4%
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Chi² = 8.14, df = 7 (P = 0.32), I² = 14.0%
0.01 0.1 1 10 100
Favours SSRI Favours SNRI

1

Figure 477: Response (ITT)


Experimental
Control
Risk Ratio
Risk Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI
M-H, Random, 95% CI
87.4.1 Duloxetine versus escitalopram
Jiang 2017 10 10 16 16 4.7% 1.00 [0.86, 1.17]
Khan 2007 62 138 83 140 2.8% 0.76 [0.60, 0.95]
Nierenberg 2007 92 273 94 274 2.7% 0.98 [0.78, 1.24]
Wade 2007 112 151 115 144 5.8% 0.93 [0.82, 1.05]
Subtotal (95% CI) 572 574 16.1% 0.93 [0.83, 1.03]
Total events 276 308
Heterogeneity: Tau² = 0.00; Chi² = 4.65, df = 3 (P = 0.20); I² = 36%
Test for overall effect: Z = 1.39 (P = 0.16)
87.4.2 Duloxetine versus fluoxetine
Goldstein 2002 42 70 17 33 1.2% 1.16 [0.79, 1.71]
Study F1J-MC-HMAQ - Study Group B 40 82 15 37 0.9% 1.20 [0.77, 1.88]
Subtotal (95% CI) 152 70 2.1% 1.18 [0.88, 1.58]
Total events 82 32
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.91); I² = 0%
Test for overall effect: Z = 1.12 (P = 0.26)
87.4.3 Duloxetine versus paroxetine
Detke 2004 128 188 64 86 4.6% 0.91 [0.78, 1.07]
Eli Lilly HMAT-A 28 84 38 89 1.2% 0.78 [0.53, 1.15]
Goldstein 2004 44 91 34 87 1.5% 1.24 [0.88, 1.73]
Hao 2014 86 140 74 141 3.3% 1.17 [0.95, 1.44]
Higuchi 2009 38 75 78 148 2.2% 0.96 [0.73, 1.26]
Lee 2007 144 238 157 240 5.3% 0.92 [0.81, 1.06]
Perahia 2006 129 196 59 97 3.7% 1.08 [0.90, 1.31]
Subtotal (95% CI) 1012 888 21.7% 1.00 [0.91, 1.10]
Total events 597 504
Heterogeneity: Tau² = 0.00; Chi² = 8.53, df = 6 (P = 0.20); I² = 30%
Test for overall effect: Z = 0.07 (P = 0.94)
87.4.4 Venlafaxine versus citalopram
Allard 2004 54 76 55 75 3.4% 0.97 [0.79, 1.18]
Subtotal (95% CI) 76 75 3.4% 0.97 [0.79, 1.18]
Total events 54 55
Heterogeneity: Not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
87.4.5 Venlafaxine versus escitalopram
Bielski 2004 47 101 57 101 2.2% 0.82 [0.63, 1.08]
Montgomery 2004 113 145 113 148 5.9% 1.02 [0.90, 1.16]
Subtotal (95% CI) 246 249 8.0% 0.95 [0.76, 1.17]
Total events 160 170
Heterogeneity: Tau² = 0.01; Chi² = 2.24, df = 1 (P = 0.13); I² = 55%
Test for overall effect: Z = 0.51 (P = 0.61)
87.4.6 Venlafaxine versus fluoxetine
Alves 1999 26 40 28 47 1.6% 1.09 [0.79, 1.51]
Clerc 1994 23 34 17 34 1.1% 1.35 [0.90, 2.04]
Costa 1998 158 196 156 186 7.3% 0.96 [0.88, 1.06]
DeNayer 2002 37 73 27 73 1.2% 1.37 [0.94, 1.99]
Diaz-Martinez 1998 37 70 45 75 2.0% 0.88 [0.66, 1.18]
Dierick 1996 107 153 95 161 4.3% 1.19 [1.00, 1.40]
Kornaat 2000 33 79 33 77 1.3% 0.97 [0.68, 1.41]
Nemeroff 2007 51 102 45 104 1.9% 1.16 [0.86, 1.55]
Rudolph 1999 54 100 52 103 2.3% 1.07 [0.82, 1.39]
Schatzberg 2000 59 104 52 100 2.4% 1.09 [0.85, 1.40]
Sheehan 2009b 35 95 27 99 1.0% 1.35 [0.89, 2.05]
Tsai 2000 24 33 22 33 1.6% 1.09 [0.79, 1.50]
Tylee 1997 81 171 98 170 3.3% 0.82 [0.67, 1.01]
Tzanakaki 2000 30 55 28 54 1.4% 1.05 [0.74, 1.50]
Subtotal (95% CI) 1305 1316 32.8% 1.05 [0.97, 1.14]
Total events 755 725
Heterogeneity: Tau² = 0.01; Chi² = 17.95, df = 13 (P = 0.16); I² = 28%
Test for overall effect: Z = 1.19 (P = 0.23)
87.4.7 Venlafaxine versus paroxetine
Casabona 2004 43 58 29 56 1.9% 1.43 [1.07, 1.92]
Hwang 2004 43 52 48 53 4.8% 0.91 [0.78, 1.06]
Owens 2008 29 44 26 42 1.7% 1.06 [0.77, 1.46]
Subtotal (95% CI) 154 151 8.3% 1.10 [0.81, 1.49]
Total events 115 103
Heterogeneity: Tau² = 0.06; Chi² = 8.88, df = 2 (P = 0.01); I² = 77%
Test for overall effect: Z = 0.60 (P = 0.55)
87.4.8 Venlafaxine versus sertraline
Mehtonen 2000 49 75 41 72 2.3% 1.15 [0.88, 1.49]
Shelton 2006 48 78 39 82 2.0% 1.29 [0.97, 1.72]
Sir 2005 56 84 56 79 3.2% 0.94 [0.76, 1.16]
Subtotal (95% CI) 237 233 7.5% 1.10 [0.90, 1.33]
Total events 153 136
Heterogeneity: Tau² = 0.01; Chi² = 3.54, df = 2 (P = 0.17); I² = 43%
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 3754 3556 100.0% 1.01 [0.97, 1.06]
Total events 2192 2033
Heterogeneity: Tau² = 0.00; Chi² = 49.37, df = 35 (P = 0.05); I² = 29%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Chi² = 6.05, df = 7 (P = 0.53), I² = 0%
0.01 0.1 1 10 100
Favours SSRI Favours SNRI

1

Figure 478: Discontinuation due to SEs



Figure 479: Discontinuation due to any reason including SE


Experimental
Control
Risk Ratio
Risk Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI
M-H, Random, 95% CI
87.6.1 Duloxetine versus escitalopram
Khan 2007 47 138 30 140 4.1% 1.59 [1.07, 2.35]
Nierenberg 2007 85 273 66 274 7.2% 1.29 [0.98, 1.70]
Wade 2007 37 151 32 144 3.7% 1.10 [0.73, 1.67]
Subtotal (95% CI) 562 558 15.0% 1.31 [1.08, 1.60]
Total events 169 128
Heterogeneity: Tau² = 0.00; Chi² = 1.60, df = 2 (P = 0.45); I² = 0%
Test for overall effect: Z = 2.70 (P = 0.007)
87.6.2 Duloxetine versus fluoxetine
Goldstein 2002 24 70 12 33 2.2% 0.94 [0.54, 1.64]
Study F1J-MC-HMAQ - Study Group B 25 82 14 37 2.4% 0.81 [0.48, 1.36]
Subtotal (95% CI) 152 70 4.6% 0.87 [0.59, 1.27]
Total events 49 26
Heterogeneity: Tau² = 0.00; Chi² = 0.16, df = 1 (P = 0.69); I² = 0%
Test for overall effect: Z = 0.73 (P = 0.47)
87.6.3 Duloxetine versus paroxetine
Detke 2004 21 188 10 86 1.4% 0.96 [0.47, 1.95]
Eli Lilly HMAT-A 44 84 31 89 4.9% 1.50 [1.06, 2.13]
Goldstein 2004 38 91 38 87 5.2% 0.96 [0.68, 1.34]
Hao 2014 32 140 36 141 3.7% 0.90 [0.59, 1.36]
Higuchi 2009 9 75 22 148 1.3% 0.81 [0.39, 1.67]
Lee 2007 72 238 57 240 6.4% 1.27 [0.95, 1.72]
Perahia 2006 23 196 11 97 1.5% 1.03 [0.53, 2.03]
Subtotal (95% CI) 1012 888 24.5% 1.12 [0.95, 1.32]
Total events 239 205
Heterogeneity: Tau² = 0.00; Chi² = 6.44, df = 6 (P = 0.38); I² = 7%
Test for overall effect: Z = 1.31 (P = 0.19)
87.6.4 Duloxetine versus sertraline
Mowla 2016 5 31 4 32 0.5% 1.29 [0.38, 4.36]
Subtotal (95% CI) 31 32 0.5% 1.29 [0.38, 4.36]
Total events 5 4
Heterogeneity: Not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
87.6.5 Venlafaxine versus citalopram
Allard 2004 18 76 16 75 2.0% 1.11 [0.61, 2.01]
Subtotal (95% CI) 76 75 2.0% 1.11 [0.61, 2.01]
Total events 18 16
Heterogeneity: Not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
87.6.6 Venlafaxine versus escitalopram
Bielski 2004 33 101 24 101 3.3% 1.38 [0.88, 2.15]
Montgomery 2004 20 145 22 148 2.2% 0.93 [0.53, 1.63]
Subtotal (95% CI) 246 249 5.4% 1.17 [0.80, 1.71]
Total events 53 46
Heterogeneity: Tau² = 0.01; Chi² = 1.16, df = 1 (P = 0.28); I² = 14%
Test for overall effect: Z = 0.82 (P = 0.41)
87.6.7 Venlafaxine versus fluoxetine
Alves 1999 10 40 9 47 1.1% 1.31 [0.59, 2.89]
Basterzi 2009 7 21 7 22 1.0% 1.05 [0.44, 2.48]
Clerc 1994 6 34 12 34 1.0% 0.50 [0.21, 1.18]
Costa 1998 29 196 18 186 2.2% 1.53 [0.88, 2.66]
DeNayer 2002 24 73 29 73 3.5% 0.83 [0.54, 1.28]
Diaz-Martinez 1998 15 70 20 75 2.0% 0.80 [0.45, 1.44]
Dierick 1996 38 153 40 161 4.2% 1.00 [0.68, 1.47]
Heller 2009 3 15 5 14 0.5% 0.56 [0.16, 1.92]
Kornaat 2000 15 79 24 77 2.2% 0.61 [0.35, 1.07]
Nemeroff 2007 24 102 18 104 2.3% 1.36 [0.79, 2.35]
Rudolph 1999 28 100 35 103 3.7% 0.82 [0.54, 1.25]
Sheehan 2009b 42 95 32 99 4.6% 1.37 [0.95, 1.97]
Tsai 2000 14 33 16 33 2.4% 0.88 [0.51, 1.49]
Tylee 1997 47 171 46 170 5.0% 1.02 [0.72, 1.44]
Tzanakaki 2000 12 55 12 54 1.4% 0.98 [0.48, 1.99]
Subtotal (95% CI) 1237 1252 37.1% 0.98 [0.85, 1.13]
Total events 314 323
Heterogeneity: Tau² = 0.01; Chi² = 15.43, df = 14 (P = 0.35); I² = 9%
Test for overall effect: Z = 0.25 (P = 0.80)
87.6.8 Venlafaxine versus paroxetine
Hwang 2004 3 52 3 53 0.3% 1.02 [0.22, 4.82]
Owens 2008 12 44 10 42 1.3% 1.15 [0.55, 2.36]
VEN XR 367 (FDA) 46 165 28 81 4.2% 0.81 [0.55, 1.19]
Subtotal (95% CI) 261 176 5.8% 0.88 [0.63, 1.23]
Total events 61 41
Heterogeneity: Tau² = 0.00; Chi² = 0.74, df = 2 (P = 0.69); I² = 0%
Test for overall effect: Z = 0.76 (P = 0.45)
87.6.9 Venlafaxine versus sertraline
Mehtonen 2000 16 75 12 72 1.5% 1.28 [0.65, 2.51]
Shelton 2006 11 78 19 82 1.5% 0.61 [0.31, 1.20]
Sir 2005 25 84 13 79 1.9% 1.81 [1.00, 3.28]
Subtotal (95% CI) 237 233 5.0% 1.14 [0.60, 2.14]
Total events 52 44
Heterogeneity: Tau² = 0.20; Chi² = 5.73, df = 2 (P = 0.06); I² = 65%
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 3814 3533 100.0% 1.07 [0.98, 1.17]
Total events 960 833
Heterogeneity: Tau² = 0.01; Chi² = 40.25, df = 36 (P = 0.29); I² = 11%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi² = 8.66, df = 8 (P = 0.37), I² = 7.6%
0.01 0.1 1 10 100
Favours SNRI Favours SSRI

1

Figure 480: Quality of life endpoint



Test for subgroup differences: Not applicable

Figure 481: Quality of life change score



More severe: Mirtazapine versus placebo

Figure 482: Depression symptomatology at endpoint



Figure 483: Depression symptomatology change score



Figure 484: Remission (ITT)



Figure 485: Response (ITT)



Figure 486: Discontinuation due to SE



Figure 487: Discontinuation due to any reason including SE



Figure 488: Global functioning endpoint



More severe: Mirtazapine versus SSRIs

Figure 489: Depression symptomatology endpoint



Figure 490: Depression symptomatology change score



Figure 491: Remission (ITT)



Figure 492: Response (ITT)



Figure 493: Discontinuation due to SE



Figure 494: Discontinuation due to any reason including SE



More severe: Mirtazapine versus TCAs

Figure 495: Depression symptomatology endpoint



Figure 496: Depression symptomatology change score



Test for subgroup differences: Not applicable

Figure 497: Response (ITT)



Test for subgroup differences: Chi² = 0.04, df = 1 (P = 0.85), I² = 0%

Figure 498: Discontinuation due to SE



Figure 499: Discontinuation due to any reason including SE



Figure 500: Global functioning endpoint



More severe: Mirtazapine versus venlafaxine

Figure 501: Depression symptomatology endpoint



Figure 502: Depression symptomatology change score



Figure 503: Remission (ITT)



Figure 504: Response (ITT)



Figure 505: Discontinuation due to SE



Figure 506: Discontinuation due to any reason including SE



Figure 507: Sleeping difficulties change score



More severe: Mirtazapine versus trazodone

Figure 508: Response (ITT)



Figure 509: Discontinuation due to SE



Figure 510: Discontinuation due to any reason including SE



Figure 511: Global functioning endpoint



More severe: Trazodone versus placebo

Figure 512: Depression symptomatology endpoint



Figure 513: Depression symptomatology change score



Figure 514: Remission (ITT)



Figure 515: Response (ITT)



Figure 516: Discontinuation due to SE



Figure 517: Discontinuation due to any reason including SE



Figure 518: Sleeping difficulties change score



More severe: Trazodone versus SSRIs

Figure 519: Depression symptomatology endpoint



Figure 520: Depression symptomatology change score



Figure 521: Remission (ITT)



Figure 522: Response (ITT)



Figure 523: Discontinuation due to SE



Figure 524: Discontinuation due to any reason including SE



1 More severe: Trazodone versus TCAs

2 Figure 525: Depression symptomatology at endpoint



3

4 Figure 526: Depression symptomatology change score



5

Figure 527: Response (ITT)



Figure 528: Discontinuation due to SE



Figure 529: Discontinuation due to any reason including SE



More severe: Trazodone versus venlafaxine

Figure 530: Depression symptomatology endpoint



Figure 531: Depression symptomatology change score



Figure 532: Remission (ITT)



Figure 533: Response (ITT)



Figure 534: Discontinuation due to SE



Figure 535: Discontinuation due to any reason including SE



More severe: Trazodone + CBT individual versus placebo + CBT individual

Figure 536: Depression symptomatology endpoint



Figure 537: Response (ITT)



Figure 538: Discontinuation due to SE



Figure 539: Discontinuation due to any reason including SE



More severe: Trazodone + CBT individual versus amitriptyline + CBT individual

Figure 540: Depression symptomatology endpoint



Figure 541: Response (ITT)



Figure 542: Discontinuation due to SE



Figure 543: Discontinuation due to any reason including SE



More severe: Supervised high intensity exercise individual versus no treatment

Figure 544: Depression symptomatology endpoint



Figure 545: Depression symptomatology change score



Figure 546: Remission (ITT)



1 **Figure 547: Discontinuation due to any reason**



2

3 **Figure 548: Quality of life endpoint**



4

5

6 More severe: Exercise individual versus SSRI

7 **Figure 549: Depression symptomatology endpoint**



8 Test for subgroup differences: Not applicable

9 **Figure 550: Depression symptomatology change score**



10

Figure 551: Remission (ITT)



Figure 552: Discontinuation due to any reason



Figure 553: Remission at 6-12 month follow-up (ITT)



Figure 554: Quality of life endpoint



More severe: Exercise individual + AD versus AD

Figure 555: Depression symptomatology endpoint



Figure 556: Depression symptomatology change score



Figure 557: Remission (ITT)



Test for subgroup differences: Not applicable

Figure 558: Response (ITT)



Test for subgroup differences: Not applicable

Figure 559: Discontinuation due to SE



Test for subgroup differences: Not applicable

Figure 560: Discontinuation due to any reason including SE



Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.99), I² = 0%

Figure 561: Remission at 6-month follow-up (ITT)



Test for subgroup differences: Not applicable

Figure 562: Quality of life endpoint



Test for subgroup differences: Not applicable

More severe: Supervised high intensity exercise individual + sertraline versus no treatment

Figure 563: Depression symptomatology endpoint



Figure 564: Depression symptomatology change score



More severe: Exercise group versus no treatment

Figure 565: Depression symptomatology endpoint



Figure 566: Depression symptomatology change score



Figure 567: Response (ITT)



Figure 568: Discontinuation due to any reason



More severe: Supervised low/high intensity exercise group versus TAU

Figure 569: Depression symptomatology endpoint



Figure 570: Depression symptomatology change score



Figure 571: Response (ITT)



Figure 572: Discontinuation due to any reason



More severe: Supervised high intensity exercise group versus sertraline

Figure 573: Depression symptomatology change score



Figure 574: Remission (ITT)



Figure 575: Discontinuation due to any reason



Figure 576: Remission at 12-month follow-up (ITT)



More severe: Supervised high intensity exercise group versus unsupervised high intensity exercise individual

Figure 577: Depression symptomatology change score



Figure 578: Remission (ITT)



Figure 579: Discontinuation due to any reason



Figure 580: Remission at 12-month follow-up (ITT)

More severe: Exercise group + SSRI versus SSRI

Figure 581: Depression symptomatology endpoint



Test for subgroup differences: Not applicable

Figure 582: Depression symptomatology change score



Test for subgroup differences: Not applicable

Figure 583: Remission (ITT)



Figure 584: Discontinuation due to any reason



More severe: Yoga group versus waitlist

Figure 585: Depression symptomatology endpoint



Figure 586: Depression symptomatology change score



Figure 587: Discontinuation due to any reason



Figure 588: Quality of life endpoint



More severe: Yoga group versus imipramine

Figure 589: Depression symptomatology endpoint



Figure 590: Depression symptomatology change score



Figure 591: Remission (ITT)



More severe: Yoga group + any AD versus any AD

Figure 592: Depression symptomatology endpoint



Figure 593: Depression symptomatology change score



Figure 594: Remission (ITT)



More severe: Traditional acupuncture versus waitlist

Figure 595: Remission (ITT)



Figure 596: Response (ITT)



Figure 597: Discontinuation due to any reason



More severe: Acupuncture versus sham acupuncture

Figure 598: Depression symptomatology endpoint



Figure 599: Depression symptomatology change score



Figure 600: Remission (ITT)



Figure 601: Response (ITT)



Figure 602: Discontinuation due to any reason



Figure 603: Depression symptomatology change score at 1-month follow-up



Figure 604: Depression symptomatology change score at 3-month follow-up



Figure 605: Remission at 1-month follow-up (ITT)



Figure 606: Remission at 3-month follow-up (ITT)



Test for subgroup differences: Not applicable

Figure 607: Quality of life (physical health component) change score



Test for subgroup differences: Not applicable

Figure 608: Quality of life (mental health component) change score



Test for subgroup differences: Not applicable

Figure 609: Global functioning change score



Test for subgroup differences: Not applicable

More severe: Acupuncture versus SSRI

Figure 610: Depression symptomatology endpoint



Figure 611: Depression symptomatology change score



Figure 612: Response (ITT)



Figure 613: Discontinuation due to any reason



More severe: Acupuncture versus TCA

Figure 614: Depression symptomatology endpoint



Figure 615: Depression symptomatology change score



Figure 616: Discontinuation due to SE



Figure 617: Discontinuation due to any reason including SE



More severe: Acupuncture + AD versus AD

Figure 618: Depression symptomatology endpoint



Figure 619: Depression symptomatology change score



Figure 620: Remission (ITT)



Figure 621: Response (ITT)



Figure 622: Discontinuation due to SE



Figure 623: Discontinuation due to any reason including SE



Figure 624: Depression symptomatology at 1-month follow-up



Test for subgroup differences: Not applicable

Figure 625: Depression symptomatology change score at 1-month follow-up



Test for subgroup differences: Not applicable

More severe: Bright light therapy versus fluoxetine

Figure 626: Depression symptomatology change score



Figure 627: Remission (ITT)



Figure 628: Response (ITT)



Figure 629: Discontinuation due to SE



Figure 630: Discontinuation due to any reason including SE

More severe: Bright light therapy versus pill placebo

Figure 631: Depression symptomatology change score



Figure 632: Remission (ITT)



Figure 633: Response (ITT)



Figure 634: Discontinuation due to SE

Figure 635: Discontinuation due to any reason including SE



More severe: Bright light therapy + AD versus AD

Figure 636: Depression v endpoint



Test for subgroup differences: Not applicable

Figure 637: Depression symptomatology change score



Figure 638: Remission (ITT)



Figure 639: Response (ITT)



Test for subgroup differences: Not applicable

Figure 640: Discontinuation due to SE



Test for subgroup differences: Not applicable

Figure 641: Discontinuation due to any reason including SE



Test for subgroup differences: Not applicable

More severe: Bright light therapy + fluoxetine versus pill placebo

Figure 642: Depression symptomatology change score



Figure 643: Remission (ITT)



Figure 644: Response (ITT)



Figure 645: Discontinuation due to SE



Figure 646: Discontinuation due to any reason including SE



1